Can a 1950s antipsychotic help fight glioblastoma?

NCT ID NCT05190315

Completed Disease control Sponsor: Mohammed Milhem Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested whether adding chlorpromazine, an old antipsychotic drug, to standard treatment (radiation and chemotherapy) is safe for people newly diagnosed with glioblastoma, an aggressive brain cancer. Ten adults took part. The main goal was to find a safe dose and check for side effects, not to measure if the drug works against the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chlorpromazine (Thorazine)
What this could lead to: If it works, this could point toward a new, affordable addition to standard therapy for glioblastoma, potentially improving outcomes.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug may not improve survival or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse intrinsic pontine glioma glioblastoma glioma susceptibility 1 gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

University of Iowa Hospitals & Clinics

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.